Search Filters:

The items contained in the list are being used to filter the search results. Click them to remove them from the search filter.
Displaying 281 - 300 of 669
PIPS Search Results
PIP Number Active Substance Sort descending Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published
MHRA-100874-PIP01-23
  • PEMBROLIZUMAB
  • Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)
  • Treatment of Hodgkin lymphoma
  • Keytruda
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No 19/12/2023
MHRA-100240-PIP01-21-M01 (update)
  • BOSUTINIB
  • Treatment of chronic myeloid leukaemia (CML)
  • Bosulif
  • Bosulif
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100240-PIP01-21-M02 (update)
  • BOSUTINIB
  • Treatment of chronic myeloid leukaemia (CML)
  • Bosulif
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 25/05/2023
MHRA-100258-PIP01-21-M01 (update)
  • Fully human IgG1 RB-1 YTE anti-RSV F monoclonal antibody (MK-1654)
  • Prevention of lower respiratory tract infection caused by respiratory syncytial virus
  • Not available yet
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100238-PIP01-21-M01 (update)
  • AVELUMAB
  • Treatment of malignant neoplasms of the CNS, lymphoid tissue and other malignant neoplasms.
  • Bavencio
  • Bavencio
  • Bavencio
  • Bavencio
  • Bavencio
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100260-PIP01-21-M01 (update)
  • CEMIPLIMAB
  • Treatment of all malignant neoplasms (except haematopoietic and lymphoid tissue)
  • Libtayo
  • Libtayo
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100580-PIP01-22-M01 (update)
  • CEMIPLIMAB
  • Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)
  • Libtayo
  • Cemiplimab
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 30/06/2023
MHRA-100182-PIP01-21-M01 (update)
  • Avalglucosidase alfa
  • Treatment of Pompe disease
  • Endocrinology-Gynaecology-Fertility-metabolism
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100233-PIP01-21-M01 (update)
  • CABOZANTINIB
  • Treatment of malignant solid tumours
  • Cabometyx
  • Cometriq
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Aptimetyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cabometyx
  • Cometriq
  • Cabometyx
  • Cometriq
  • Cabometyx
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100249-PIP01-21-M01 (update)
  • BUDESONIDE
  • GLYCOPYRRONIUM BROMIDE
  • FORMOTEROL FUMARATE DIHYDRATE
  • Treatment of asthma
  • Pneumology - Allergology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100249-PIP01-21-M02 (update)
  • BUDESONIDE
  • GLYCOPYRRONIUM BROMIDE
  • FORMOTEROL FUMARATE DIHYDRATE
  • Treatment of asthma
  • Trixeo Aerosphere
  • Trixeo Aerosphere
  • Trixeo Aerosphere
  • BREZTRI AEROSPHERE
  • Pneumology - Allergology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 19/12/2023
MHRA-100341-PIP01-21-M01 (update)
  • ISAVUCONAZONIUM SULFATE
  • Treatment of invasive aspergillosis
  • Treatment of mucormycosis
  • Cresemba
  • Cresemba
  • Cresemba
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100328-PIP01-21-M01 (update)
  • METRELEPTIN
  • Treatment of lipodystrophy
  • Myalepta Powder for Solution for Injection
  • Myalepta
  • Myalepta
  • Endocrinology-Gynaecology-Fertility-metabolism
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100370-PIP01-21-M01 (update)
  • EX VIVO EXPANDED AUTOLOGOUS HUMAN CORNEAL EPITHELIAL CELLS CONTAINING STEM CELLS
  • Treatment of limbal stem cell deficiency due to ocular burns
  • Holoclar
  • Holoclar
  • Holoclar
  • Ophthamology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100377-PIP01-21-M01 (update)
  • ACALABRUTINIB
  • Treatment of mature B cell neoplasms
  • calquence
  • calquence
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100352-PIP01-21-M01 (update)
  • AVAPRITINIB
  • Treatment of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)
  • AYVAKYT
  • AYVAKYT
  • AYVAKYT
  • AYVAKYT
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100352-PIP01-21-M02 (update)
  • AVAPRITINIB
  • Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)
  • AYVAKYT
  • AYVAKYT
  • AYVAKYT
  • AYVAKYT
  • AYVAKYT
  • AYVAKYT
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No 19/12/2023
MHRA-100164-PIP01-21-M01 (update)
  • Nirmatrelvir
  • RITONAVIR
  • Treatment of coronavirus disease 2019 (COVID-19)
  • Prevention of coronavirus disease 2019 (COVID-19)
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 27/09/2022
MHRA-100164-PIP01-21-M02 (update)
  • Nirmatrelvir
  • RITONAVIR
  • Treatment of coronavirus disease 2019 (COVID-19)
  • Prevention of Coronavirus Disease 2019 (COVID-19)
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 30/06/2023
MHRA-100164-PIP01-21-M03 (update)
  • Nirmatrelvir
  • RITONAVIR
  • Treatment of coronavirus disease 2019 (COVID-19)
  • Prevention of coronavirus disease 2019 (COVID-19)
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Paxlovid
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No 30/04/2024